News Column

Nodality, Inc. Announces Publication of Promising Data in Melanoma in Journal of Translational Medicine

May 28, 2014

Nodality’s SCNP Platform Holds Strong Potential in Aiding the Development of New Cancer and Immuno-Oncology Treatments

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies by revealing functional systems biology, announced today promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality’s SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents. According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality’s researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

“While there has been exciting recent progress in the treatment of melanoma, new therapies have been found to benefit only a subset of patients and are often associated with significant adverse effects,” commented Laura Brege, Nodality’s President and Chief Executive Officer. “With our highly sensitive and reproducible SCNP platform, we are able to attain a deep, functional understanding of how the immune system behaves in the presence of tumor cells and how cancer cells vary in their response to approved and promising development-stage therapies. In light of SCNP’s broad range of capabilities and potential applications, we believe our technology can play an essential role in advancing pipelines of targets and therapeutics to deliver the next generation of drugs for cancer and other major illnesses.”

For access to the JTM article, titled “Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification,” please visit http://www.translational-medicine.com/content/12/S1/O13.

About Single Cell Network Profiling

Contemporary pharmaceutical research and development remains challenged in producing drugs to revolutionize the treatment of many of our most intractable diseases, such as cancer, autoimmune diseases, and diseases of the cardiovascular system and central nervous system, demanding higher levels of biological understanding to inform effective drug development decisions. Nodality’s proprietary Single Cell Network Profiling (SCNP), originally developed at Stanford University, is a multiparametric flow cytometry-based assay that provides unprecedented insights into diseases by characterizing cell signaling networks in millions of cells at the single cell level. SCNP measures functional protein pathway signaling networks within and between cells, identifying rare cell subsets, such as drug-resistant cells, revealing epigenetic changes in cells, and perceiving cell-cell interactions in complex disease states.

About Nodality

Nodality is advancing drug discovery, therapeutic development, and precision medicine by delivering critical and clinically actionable information to bridge gaps left by traditional R&D approaches. Nodality’s proprietary functional biology platform, Single Cell Network Profiling (SCNP), unlocks highly complex intracellular mechanisms and cellular interactions in human diseases and has the power to shed light on some of the pharmaceutical industry’s most challenging R&D problems. SCNP enables smarter spending decisions and is applicable across a very broad therapeutic landscape and throughout the full discovery and development process. Nodality has established multi-year strategic collaborations with UCB Pharma S.A. (Euronext Brussels: UCB), Pfizer (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ), utilizing its SCNP technology to assist the development of new therapeutic compounds.




Nodality, Inc.

Company:

Daniel Dornbusch, 650-827-8000

daniel.dornbusch@nodality.com

or

Burns McClellan

Media:

Justin Jackson, 212-213-0006, ext. 327

jjackson@burnsmc.com


Source: Nodality, Inc.


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Business Wire